Optimizing Malaria treatment for HIV-malaria co-infected individuals by addressing drug interactions between artemisinin-based combination therapies and antiretroviral drugs (OPTIMAL)

Malaria and HIV have significant interactions at various levels; the geographical and epidemiological overlap increases risk for co-infection and co-treatment, HIV immunosuppression increases malaria incidence, parasitaemia, severity and risk for poor treatment outcomes including mortality and adverse pregnancy outcomes such as anemia and low birth weight. Malaria infection increases HIV viral replication and viral load. Both malaria and HIV are treated with combination therapy to enhance treatment outcomes and reduce risk for development of resistance, consequently creating potential for drug-drug interactions (DDIs) when the two diseases are treated concomitantly.

EDCTP Grants

Drug-based Strategies
Vulnerable Populations

Apr 2019 — Mar 2024

$560,853

Uganda